Non-Opioid Drugs Market for Chronic Pain Management Poised to Grow at a Healthy Annualized Rate 40%

LONDON - Sept. 12, 2018 - PRLog -- Roots Analysis has announced the addition of "Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025" report to its list of offerings.

Tapish Dogra, the principal analyst, stated, "In order to address the growing concerns related to opioid abuse, various companies have come up with novel non-opioid alternatives. Presently, over 145 non-opioid product candidates are marketed / under evaluation across various stages of development for the management of chronic pain caused due to various clinical conditions."

The report presents opinions on several key aspects of the market. Among other elements, it includes:

1.  A detailed assessment of the current market landscape of drugs being developed for the treatment of chronic pain, providing information on their respective developer(s), phase of development, type of molecule, indication, mechanism of action and route of administration.

2. An in-depth analysis of the product pipeline and developer companies, featuring [A] a mirror analysis highlighting the relative popularity of different disease indications based on the number of molecules available / under development for each indication and the number of companies involved, [B] a logo landscape of the various industry players involved in this domain, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large), [C] a heptagon representation highlighting the distribution of marketed and pipeline molecules based on their respective mechanisms of action, and [D] a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type.

3. An analysis highlighting the key unmet needs across chronic pain, featuring insights generated from data sourced from patient blogs, recent scientific publications, social media posts and the views of key opinion leaders expressed on various online platforms.

4. An elaborate discussion on lifecycle management strategies, describing how different companies are using various methods to prolong patent age and, thereby, expand marketing exclusivity in order to exploit the revenue generation potential of their proprietary products. The section also includes detailed case studies elaborating on diverse lifecycle management strategies of marketed drugs that are nearing patent expiry.

5. Comprehensive profiles of drugs that are in phase III of clinical development with information on developer companies (including location of headquarters and year of establishment), type of molecule, mechanism of action, current status of development, route of administration, information on clinical trials and key developments (if available).

6. A detailed assessment of the current market landscape of various devices that are being developed for chronic pain management, highlighting information on developer (size of company and location of headquarters), mechanism of action (electrical stimulation, electromagnetic pulse, heat therapy, light therapy, radiofrequency stimulation and others), site of application on the body (head, arm, knees and other areas), modality of the device (invasive and non-invasive), and treatment requirements (at home and at hospitals / outpatient clinics), and type of device (wearable, hand-held and implants).

7.  An insightful 2X2 competitive analysis for the various devices, highlighting the most important products based on the modality of device, treatment requirement, type of device, and supplier power (based on size of employee base of the company). The chapter also includes profiles of devices that emerged as relatively superior (based on the analysis); each profile features details on the developer (location of headquarters and year of establishment), approval year, mechanism of action, key features and key developments.

8. An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (related to both technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements and others.

9. An analysis of investments made at various stages of product development; these include seed financing, venture capital financing, debt financing and grants / awards, received by companies that are operating in this domain.

Dogra further added, "The future holds significant promise for companies working to develop novel non-opioid therapeutics and pain management devices. In fact, drugs which have received / are expected to receive approval for the treatment of migraine by late 2018 / early 2019 are most likely to achieve blockbuster status in the future. Further, in terms of  drug class, by 2025, the market share is likely to be distributed amongst anti-CGRP drugs (54%), followed by NGF inhibitors (20%) and calcium / sodium channel blockers (16%)."

The research covers detailed profiles and assesses service portfolios of the following companies:

1.     1^st Order Pharmaceuticals

2.     4P Therapeutics

3.     Abbott

4.     AbbVie

5.     AcelRx Pharmaceuticals

6.     AdynXX

7.     Amgen

8.     Anavex Life Sciences

9.     Araim Pharmaceuticals

10.   AVACEN Medical

11.   BIAL

12.   Boehringer Ingelheim

13.   Cara Therapeutics

14.   Cefaly

15.   DavaRay

16.   Eisai

17.   Eli Lilly

18.   ELvations Medical

19.   Grünenthal

20.   Iroko Pharmaceuticals

21.   Medtronic

22.   Merck

23.   Par Pharmaceuticals

24.   Sumitomo Dainippon Pharma

25.   Theravance Biopharma

26.   ViaTherm Therapeutics

27.   Zydus Pharmaceuticals

28.   Zynex Medical

For additional details, please visit

https://www.rootsanalysis.com/reports/market-reports/view...
or email sales@rootsanalysis.com